AUXLY CANNABIS WKN: A2JNSX ISIN: CA05335P1099 Kürzel: XLY Forum: Aktien Thema: Hauptdiskussion

IM NAMEN DES VORSTANDES "Hugo Alves" CEO Auxlys Tochtergesellschaft KGK Science erhält von Health Canada eine Lizenz für institutionelle Cannabisforschung |

Zur Info: Auxly’s Subsidiary KGK Science Receives Institutional Cannabis Research Licence from Health Canada Nachrichtenquelle: globenewswire 23.12.2020, 13:30 | 138 | 0 | 0 TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a consumer packaged goods company in the cannabis products market, is thrilled to announce that its wholly owned subsidiary, KGK Science Inc. (“KGK”) has received its Institutional Cannabis Research Licence from Health Canada pursuant to the Cannabis Act. In addition to the two project-specific cannabis research licences, and the licence to conduct sensory trials currently held by KGK, this Institutional licence provides the contract research organization with approval to conduct multiple cannabis research projects, removing the need to obtain individual research licences for each project, thereby increasing its flexibility and expediting processes at its clinical research facility located in London, Ontario. As one of the first entities in Canada to receive this expanded licence, KGK will be able to provide its clients increased access to an expansive portfolio of clinical trials in support of the development of safe and effective cannabis products. Anzeige Grüne und ESG-Anleihen: Was steckt hinter ihrem Aufstieg? FRANKFURT (Schroders) – Der Markt für grüne und soziale Anleihen wächst, entwickelt sich weiter, wird immer diversifizierter und stellt nach wie vor ein hilfreiches Instrument für größere Nachhaltigkeit dar. Was bedeutet dies für die Anleger? powered by finative “As the cannabis industry continues to evolve and we sit on the cusp of some major regulatory changes, this institutional research licence allows us to increase the pace by which we can support the industry in ensuring the safety and efficacy of cannabis products to Canadian consumers,” says KGK President and CEO Najla Guthrie. “With KGK’s in-depth expertise in the nutraceutical industry, our team of highly-trained scientific researchers, and access to state-of-the-art technologies, KGK continues to be positioned to lead the cannabis industry in research as it moves into its next stage of growth.” ON BEHALF OF THE BOARD "Hugo Alves" CEO Auxly’s Subsidiary KGK Science Receives Institutional Cannabis Research Licence from Health Canada | wallstreet-online.de - Vollständiger Artikel unter: https://www.wallstreet-online.de/nachricht/13304497-auxly-s-subsidiary-kgk-science-receives-institutional-cannabis-research-licence-from-health-canada

https://www.bloomberg.com/news/articles/2020-12-20/aphria-tilray-deal-is-a-bet-on-euro-pot-cannabis-weekly

👌

Echt eine Trauerfeier 🤦🏼

http://www.globenewswire.com/news-release/2020/12/17/2146885/0/en/Kolab-Project-Launches-232-Series-Limited-Edition-Live-Terpene-510-Vape-Cartridges.html

Autsch! Falsche Richtung

so isses...........

Wochentendenz auch eindeutig nach unten.............

👌 Laut Marijuana Business Daily und El Sol de Mexico hat das mexikanische Unterhaus beschlossen, die Debatte über das Gesetz zur Legalisierung von Cannabis auf Februar 2021 zu verschieben.

https://www.benzinga.com/markets/cannabis/20/12/18716756/mexico-sees-another-delay-in-cannabis-bill-debate

@knoblauch falsches forum. Verkaufslizenzen hat Auxly schon lange.

https://inult.com/tag/delta-organics/ Montag 🚀📈👍

CA00851F1062 geheimtip verkauflizenz erhalten 🚀🚀🚀 MONTAG

So richtigen Zug Richtung 30 Cent die jemand am Jahresende hier gesehn hat, hat die Aktie ja aktuell nicht

Ich hoffe mal nicht 👌